Developing the Next Generation of Clinical Trial Chief Investigators

Developing the Next Generation of Clinical Trial Chief Investigators

More than 50 delegates attended a workshop at the International Clinical Trials Methodology Conference (ICTMC) in Birmingham to explore how the UK can develop and sustain the next generation of Chief Investigators (CIs) for clinical trials.

Hosted by members of the UK Registered CTU Network’s Chief Investigator Network Group (CING), the session focused on the proposed Chief Investigators of Randomised Trials: Increasing Capacity And Leadership (CRITICAL) Scheme. The initiative aims to address a recognised gap in the clinical trials landscape: whilst clinical trials and Clinical Trials Units (CTUs) operate within well-established frameworks, there is currently no formal training pathway for Chief Investigators in the UK.

The need for future trial leaders is becoming increasingly important. Demand for both commercial and investigator-led trials continues to grow, clinical research is expanding across health and social care settings, and the range of professionals taking on leadership roles is widening. At the same time, the number of clinical academics in the UK is declining, creating concerns about future research capacity.

The workshop brought together representatives from the UK Registered CTU Network, NIHR and the Academy of Medical Sciences, alongside experienced Chief Investigators and other CTU colleagues. Delegates discussed a proposed leadership pathway that would provide structured development opportunities for aspiring CIs, including learning resources, leadership training, trial development experience and mentorship.

Developing the Next Generation of Clinical Trial Chief Investigators - ICTMC 2026 Speakers
Speakers (left to right): Katherine Dew, Kerry Hood, Katie Morris, Rustam Al-Shahi Salman, Holly Speight
Developing the Next Generation of Clinical Trial Chief Investigators - ICTMC 2026 Delegates
Lively discussion with Mentimeter at ICTMC 2026!

Feedback from the session demonstrated strong support for the initiative, with 95% of respondents agreeing that a scheme such as CRITICAL is needed. Delegates also offered valuable suggestions on accreditation, educational resources, continuing professional development and collaboration across the research community. Several attendees also volunteered to contribute to the scheme’s future development.

The next step will be to secure funding for the discovery phase of the project. In the meantime, the UK Registered CTU Network will continue to engage with Chief Investigators and other stakeholders to help shape the scheme and ensure it meets the needs of future trial leaders across the UK.


Find out more about CING’s remit and ongoing activities here.

Discover guidance and other useful resources for Chief Investigators here.

From uncertainty to evidence: proportionate pharmacovigilance for safer care

For World Patient Safety Day 2026, Claire Brooks, Pharmacovigilance Manager of the Oncology Clinical Trials Office at the University of Oxford looks at how pharmacovigilance and Clinical Trials Units (CTUs) can help manage uncertainty and protect participants as novel approaches to cancer prevention move into clinical trials.

World Patient Safety Day 2026 focuses on safe care for people living with noncommunicable diseases, including cancer.

Clinical trials are fundamental to improving that care, helping us understand not only whether new interventions work, but also how safely they can be used.

Pharmacovigilance (PV) – the detection, assessment, understanding and prevention of adverse events and other medicine related problems – is central to this process.

Copyright © University of Oxford Images /
John Cairns Photography – All rights reserved.


Pharmacovigilance challenges in novel interventions

One of the biggest challenges for PV arises when planning trials of novel interventions: how do we plan for risks that we do not yet fully understand?

This is particularly relevant to our work in precision prevention. Precision prevention in cancer research means using detailed biological and genetic data to intercept and stop cancer before it starts in high-risk individuals.  Participants may have undergone curative intent surgery for early-stage cancer or carry an inherited genetic variant that increases their future cancer risk.

In conventional oncology trials, participants with advanced cancer are likely to already be seriously unwell and may receive treatments such as chemotherapy, with well-characterised toxicities. In a prevention trial, one of the challenges is that these populations are neither healthy volunteers nor people with active disease; the intervention is intended to prevent. There is therefore a particularly low tolerance for treatment related harm.

Copyright © University of Oxford Images /
John Cairns Photography – All rights reserved.

At the same time, our preventive interventions are novel and entering first-in-human (FIH) studies, meaning that initially there is limited human safety information available. This uncertainty appropriately leads to a cautious approach to safety monitoring, even where the actual level of risk to participants is not yet known.

This highlights an important distinction: uncertainty about risk is not necessarily the same as evidence of high risk.


Different trials, different safety contexts

Three vaccine trials supported by the Oncology Clinical Trials Office (OCTO) illustrate the challenge.

LungVax is investigating a ChAdOx2-based vaccine designed to prevent or delay recurrent or new non-small cell lung cancer in people at increased risk. Although its use in this setting is novel, the ChAdOx2 technology builds on Oxford’s experience with viral-vector vaccines.

Learn more about LungVax here.

LungVax Trial Logo - World Patient Safety Day 2026

INTERCEPT-Lynch presents a different situation. It is testing mRNA-4194 in people with Lynch syndrome, with the aim of training the immune system to recognise and remove abnormal cells before they develop into cancer.

The study is the first time mRNA-4194 has been given to people, meaning that its side-effect profile is necessarily uncertain.

Learn more about INTERCEPT-Lynch here.

INTERCEPT Lynch Trial Logo - World Patient Safety Day 2026

VISTA, meanwhile, is evaluating ITOP1, another first-in-human cancer vaccine, but in people with resectable oesophageal cancer receiving chemotherapy and surgery.

Its Phase I safety lead-in involves eight participants receiving staggered vaccine doses, with safety assessed before the trial progresses to its randomised Phase II stage.

Learn more about VISTA here.

VISTA Trial Logo - World Patient Safety Day 2026

All three involve novel cancer vaccines, but their participants, underlying health, accompanying treatments and existing knowledge about the interventions differ considerably.

This is why “novel” cannot, by itself, define the appropriate pharmacovigilance approach.


What does proportionate pharmacovigilance mean?

At the start of a trial, caution is appropriate. Trial teams must decide which adverse events to collect, how they will be assessed and reviewed, and which findings might require additional action or even a pause in treatment. But PV should not be static.

As participants receive an intervention, uncertainty gradually begins to be replaced by evidence. Sometimes that evidence may identify a potential risk requiring additional monitoring. Equally, accumulating experience may provide reassurance.

Good PV means being prepared to respond to both.

It can be tempting to assume that collecting more safety information automatically makes a trial safer. However, every reporting requirement creates work for participants, research sites and trial teams. The important question is therefore not simply “How much safety data can we collect?”, but “Which information will genuinely help us identify and manage important risks?”

Proportionate PV is not about doing less to protect participants. It is about focusing attention where it contributes most to their safety.

A low rate of SAEs may be reassuring, but it does not establish that the interventions are risk-free. Early phase trials involve relatively small numbers of participants, and rare adverse reactions may only become apparent after much greater exposure.

Nevertheless, an absence of SAEs is part of the accumulating safety evidence. The information available when planning a second or third trial is therefore different from that available before the first participant received the intervention.

This raises an important question: should our approach to safety monitoring remain unchanged as our knowledge of an intervention grows?


How the Registered CTU model supports safer trials

This is where the Clinical Trials Unit model is particularly valuable.

PV does not operate in isolation. CTUs bring together multidisciplinary expertise in trial management, statistics, data management, regulatory and quality requirements. This allows individual safety reports to be considered alongside accumulating trial data and the wider clinical picture.

Importantly, the learning does not end with an individual study. Experience from one trial should inform the design of the next, allowing assumptions made before first-in-human exposure to be revisited as evidence grows.

For novel interventions, we inevitably begin with uncertainty. Good pharmacovigilance means putting appropriate safeguards in place while remaining willing to adapt as knowledge develops.

By bringing together the expertise needed to interpret emerging safety information and carrying that learning from one trial to the next, CTUs can help turn uncertainty into evidence, and evidence into safer care.


To keep up to date with the work of the Network follow us on LinkedIn or Bluesky.

Updated guidance now available for Chief Investigators and Clinical Trials Units

We’re pleased to share an updated version of our guidance for Chief Investigators (CIs) and Clinical Trials Units (CTUs), designed to support the development of effective and productive clinical trial collaborations.

Originally developed in 2018 by the UK Registered CTU Network’s Efficient Trial Conduct Group, the guidance was created to support discussions and expectations when setting up new trial collaborations. Since then, it has been adopted and adapted by a number of CTUs across the Network.

The document has now been reviewed and refreshed by a sub-group led by Katie Morris, Director of the Birmingham CTU and Professor of Obstetrics and Maternal Fetal Medicine, on behalf of the Chief Investigators’ Network Group, ensuring that it reflects current practice and continues to support strong, productive working relationships between Chief Investigators and CTUs.

Thank you to Katie and everyone involved in reviewing and updating this valuable resource.

You can find this and other useful resources here.


To keep up to date with the work of the Network follow us on LinkedIn or Bluesky.

New Chair sought for Network’s Executive Group

The UK Registered Clinical Trials Unit (CTU) Network is seeking a highly experienced person with expertise in clinical trials to chair its Executive Group.

The position is becoming vacant due to the current Chair, Simon Denegri, OBE, reaching the end of his maximum term.

The successful candidate will have a wealth of experience, knowledge, and acumen within the field of non-commercial/academic clinical trials research, demonstrate an excellent understanding of best practice as well as current drivers for change.

A more detailed role description, and information on how to apply, can be found below in the applicant information pack below.

As the collective voice of non-commercial and academic clinical trials units, the Network plays an important role in engaging with Government, funders, regulators, and patients to improve and strengthen clinical research in the UK. The Network is seen internationally as an exemplar for the development of national clinical trials support. It was established in 2007, and its members are committed to setting and sharing good practice and improving standards in clinical trials.

Our network is funded by its members, and major funders have representation on the Network’s Executive Group, this includes Cancer Research UK, NIHR, as well as devolved nations representation such as Health and Social Care Research Wales.

The deadline for applications is 6pm on 23 October 2026.

Designing Trials for and with Breastfeeding Mothers*

Breast milk and breastfeeding benefit mother, child, economy and environment, yet breastfeeding rates remain suboptimal globally, and particularly so in the UK. With rising chronic disease burden and health inequalities, there is an urgent need for high-quality evidence for and with breastfeeding women* to identify barriers and strategies to promote breastfeeding and improve outcomes.

Research Inclusion

Women’s health research is already underrepresented, and breastfeeding women face further exclusions. They are routinely excluded from drug trials by default due to concerns about infant safety, leaving women and clinicians to make decisions without essential information on risks and benefits of a medicine during breastfeeding. As a result, women may avoid needed treatment, take an incorrect dose or stop breastfeeding altogether.

There’s a recent push from the WHO, European Medicines Agency, researchers and others for the inclusion of pregnant and breastfeeding people in clinical trials with special considerations outlined, including undertaking lactation studies to determine drug transfer as a first step. This should mean fewer women are unnecessarily excluded from research or discouraged from breastfeeding, and better data to inform appropriate clinical practice.

Photo of Sarah Dib - Designing Trials for and with Breastfeeding Mothers
Sarah Dib, PhD, RD

Mothers Matter Too

Breastfeeding research and public health messaging often focus on benefits to the infant. However, extensive evidence shows that women benefit too, including reduced risks of breast and ovarian cancers and type 2 diabetes. Trials should ask how an intervention could benefit the mother. One example of this is evidence from randomised controlled trials showing that breastfeeding relaxation interventions reduce maternal stress, alter breast milk composition, improve infant growth and potentially result in more favourable infant behaviour, across different settings and populations. EXPRESS was one such trial undertaken at the NPEU CTU investigating the use of a relaxation audio for mothers expressing milk for their very preterm infant.

Practical Considerations

There are several further practical points trial teams should address:

Design:

Consider barriers to participation, including the demanding postpartum period, lack of support, and cultural hesitancy or mistrust in research. Involving mothers, breastfeeding charities, and partners/families in the study planning would help identify and reduce these barriers. It is also worth considering how a study itself could interfere with breastfeeding. The DOLFIN trial, which investigated a nutritional supplement for neonates, provides a good example of how to manage this. The study developed breastfeeding-specific resources (videos, leaflets), offered different delivery methods (syringe, teat, finger, cup) and engaged national breastfeeding charities to ensure that breastfed infants could be included without the supplement interfering with feeding.

There is currently no core outcome set for breastfeeding outcomes, with considerable variation in the endpoints, time points and definitions used, making it difficult to pool data or compare findings across studies.

Outcomes:

Exclusive breastfeeding status is often assessed by maternal recall over varying periods (24-hours, 7-days or since birth) so exact definitions and time points should always be reported for transparency.

Milk volume is another outcome of interest, often assessed by feeding diaries or test-weighing. However, these techniques can be time-consuming and burdensome. Where possible, isotope techniques such as deuterium oxide dose-to-mother offer a more objective method, and can also assess exclusive breastfeeding status more reliably than maternal recall which is prone to recall and social desirability biases.

Trials investigating breast milk itself also need to account for its dynamic nature, since composition changes within a feed, throughout the day and across time. Standardising sampling techniques to account for time of day, expression method, and breast fullness and emptying improves both internal validity and comparability across studies.

Data collection:

Collect data at home visits or during routine appointments whenever possible; offer flexibility around feeding schedules and routine care; provide spaces to feed or express milk and allow for longer visit times to reduce participation barriers.

Dissemination:

Share findings back in collaboration with breastfeeding mothers.  

Overall, there is a need for trials that are designed with and for breastfeeding women in mind to ensure their inclusion and representation in research and data, and to improve breastfeeding and other health outcomes.

Sarah Dib, PhD, RD
NIHR Development and Skills Enhancement Award Fellow, undertaking a placement at the National Perinatal Epidemiology Unit Clinical Trials Unit (NPEU CTU)
Honorary Research Fellow, UCL Great Ormond Street Institute of Child Health       
Research Associate, Leicester Diabetes Centre and NIHR Leicester Biomedical Research Centre 


* We use the term ‘breastfeeding women’ and ‘breastfeeding mother’ to refer to those who are providing breast milk. We acknowledge that not all people who provide breast milk identify as women or mothers, and it is important that evidence-based care for maternity, perinatal and postnatal health is inclusive.

The Network becomes the UK Registered CTU Network

The UK Clinical Research Collaboration (UKCRC) Registered CTU Network is proud to launch a new visual identity and name, as we become the UK Registered CTU Network.

This change marks an important evolution for the Network. It reflects both the maturity of our community and our role as a nationally recognised collective of Clinical Trials Units (CTUs) supporting high‑quality, publicly funded clinical research across the UK. 

While our visual identity and name are changing, our purpose remains the same: to support excellence, collaboration, efficiency and impact in clinical trials through a strong, connected CTU community. 

The Network becomes the UK Registered CTU Network - new logo
A picture of Lucy Chappell

Prof Lucy Chappell, DHSC Chief Scientific Adviser

“This shift to a self-sustaining, self-governed model is a testament to how far the UK Registered CTU Network has come, showcasing a vibrant, effective, and thriving community, and one that is poised for continued success in the years ahead. The CTU Network is well placed to drive forward the innovation that will keep UK clinical trials at the forefront of world-leading science and research.”

Dr Graham Cadwallader, Head of Clinical Research, Cancer Research UK

“The UK Registered CTU Network is central to the UK’s ability to deliver world‑leading clinical research, and Cancer Research UK is proud to champion its continued evolution. Membership of the network is a clear marker of excellence, demonstrating high standards in trial design and delivery. This update marks an important milestone for a community that underpins innovation, quality, and excellence in trials, that advances research that benefits patients worldwide.”

Why the change? 

Over recent years, the Network has grown in scale, reach, and influence. Our work increasingly extends beyond formal structures, into broader engagement with funders, policymakers, industry partners, and international collaborators including membership of the DHSC’s UK Clinical Research Delivery (UKCRD) Programme Board. In this context, the name UK Registered CTU Network provides greater clarity. 

The Network continues to operate through its established governance groups, registration processes, and group activity, ensuring continuity, quality, and assurance. 

The updated visual identity supports this maturation and independence. It presents a confident, and cohesive look, designed to work consistently across our digital, print, and event settings. Together, the new name and visual identity help us to communicate more clearly who we are, what we do, and the broad value we bring. 

What does the UK Registered CTU Network represent? 

The UK Registered CTU Network brings together registered CTUs from across the UK to: 

  • Support high standards in the design, conduct, and analysis of clinical trials. 
  • Enable collaboration, innovation and shared learning.
  • Provide a collective voice in national and international clinical research discussions. 
  • Strengthen the visibility and impact of publicly funded clinical trials. 

What is changing – and what is not? 

What’s changing 

  • Our name: UK CRC Registered CTU Network → UK Registered CTU Network. 
  • Our visual identity: refreshed branding.
  • How we present ourselves externally across communications and events. 

What’s staying the same 

  • Our commitment to maintaining rigorous standards and quality assurance in publicly funded research. 
  • Our collaborative, community‑led approach. 
  • Our support for UK‑wide clinical research via sharing of knowledge with other networks, funders, regulators, and government bodies.

Existing members remain members of the Network, and there is no change to registration status or expectations as a result of this branding update. 

Launch and next steps 

Our new identity will be rolled out across Network communications, the website, and upcoming events over the coming months. Members and stakeholders will begin to see the UK Registered CTU Network name and visual identity used from this point forward. 


Prof Kerry Hood, Director of the UK CTU Network

“We are grateful to our CTU community and partners who continue to shape and strengthen the Network. This update allows us to reflect who we are today – and supports where we are going next.”

Read our Frequently Asked Questions here.


You can learn more about the Network’s commitments in its Strategy for 2025 – 2030 here.

To keep up to date with the work of the Network follow us on LinkedIn or Bluesky.

South Asian Heritage Month 2026: Unity in Diversity

South Asian Heritage Month was officially launched in 2020, with more than 150 official and unofficial events taking place across the UK. Since then, it has grown into an annual celebration, recognised both nationally and internationally, bringing together workplaces, schools, cultural organisations and communities to celebrate the rich histories, cultures and contributions of South Asian people.  This year’s theme is Unity in Diversity.

Beyond the celebrations, the South Asian Heritage Trust plays an important role in driving lasting change. Through its work, the Trust helps organisations and communities better understand and value heritage, challenge inequalities, and create environments where everyone feels a genuine sense of belonging.

Our commitment to diversity in trials

Diversity in clinical trials is essential to ensuring research is equitable, relevant, and beneficial to all communities. This applies not only to those who participate in trials, but also to the teams that design, deliver and lead them. The Network is committed to promoting inclusive trial design, increasing representation across diverse populations, and addressing barriers that may prevent people from taking part in research.

South Asian Heritage Month provides an opportunity to recognise and highlight the many ways Clinical Trials Units are engaging with, supporting, and celebrating South Asian communities.

Read some of the stories and initiatives below to find out more.


Using AI to improve research inclusion

Assessing the accuracy and accessibility of AI vs human translations of patient-facing clinical trial documents

The Southampton Clinical Trials Unit (SCTU) has been conducting a project to look at whether Artificial Intelligence (AI) could be used to provide translations of clinical trial documents for people with limited English proficiency, including those of South Asian heritage, and thereby help improve research inclusion and diversity among trial participants.

Research participation by people from diverse backgrounds is essential to understand the generalisability of trial findings. However, people taking part in clinical trials do not always represent the race and ethnicity of the whole population or those affected by different diseases and this is likely to have detrimental consequences for the health of underserved groups and may increase social inequalities in health

Being unable to read or speak English is an exclusion criterion for many trials and therefore people from ethnic minority and migrant backgrounds may be excluded. But translation is expensive and often not covered by trial budgets.

AI offers quick, free machine translation but evidence for its accuracy and accessibility is lacking, particularly in medical fields where complex information needs to be conveyed accurately and clearly.

In this project, the team is comparing machine translation of trial documents such as Participant Information Sheets (PIS) and Informed Consent Forms (ICF) using AI applications to translations done by professional human translators in several different languages, including Punjabi, and assessing them for accuracy, tone and potential loss of nuance using a dual-layered qualitative analysis.

Final analysis and write-up is currently ongoing and the results of the project will be presented in an oral presentation at the International Clinical Trials Methodology Conference in September 2026.

Potential relevance and future impact

As part of the analysis, the project has involved working with native Punjabi speakers (as well as speakers of Polish and Mandarin) who have reviewed the translated documents and given experiential feedback as to the quality and accessibility of the translations.

Following this foundational pilot, the SCTU team has secured funding to further evaluate AI translation tools in real-world trial settings, assessing uptake of translated documents and conducting qualitative interviews with recruitment staff and trial participants. This will involve more languages, including other South Asian languages, and will provide further evidence on the accuracy and acceptability of AI translations, their potential impact on diversity of trial participants, and the creation of best practice guidelines for future use of AI translations by trial teams.

The Southampton Clinical Trials Unit has expertise in methodology research and embedding studies into trials through SWATs and other qualitative practices. The project lead for this project sits on several national networks looking at research inclusion in clinical trials, including as chair of the UK Registered CTU Network Research Inclusion Group and as a member of the Cancer Research UK CTU Research Inclusion Group and UK Clinical Research Inclusion Group.

Find out more about this project here – https://www.southampton.ac.uk/ctu/methodology.ai-translation.page


Managing Type 2 Diabetes in Nepal: HoDiRECT and CoDIRECT

Type 2 diabetes (T2D) has been emerging as a major public health problem in Nepal. It affects 8.5 percent of the population, or two million people, who face increased morbidity, mortality, and healthcare costs. Modern diabetes care and medications are largely unavailable. Current management focuses on cheap pharmaceutical interventions, yet growing evidence suggests that dietary modification may be more effective and can play a pivotal role for long-term health outcomes by achieving remission of T2D.

HoDiRECT and CoDiRECT are designed to evaluate a community-based diet programme in achieving and sustaining T2D remission. The intervention emphasizes whole-food, nutrient-dense dietary patterns tailored to the local context and delivered through community support structures. It incorporates practical dietary education, including food preparation demonstrations. By leveraging a real-world, community-driven approach, these aim to generate evidence on the feasibility, effectiveness, and long-term impact of dietary intervention in T2D management and broader metabolic health improvements.

The HoDiRECT Nepal project demonstrated the feasibility of a low-calorie traditional Nepali diet for diabetes remission. It concluded that improving diabetes literacy within communities and emphasizing the role of diet, as a potentially more effective intervention than medication, is critical. Consistent, confident and supportive engagement from healthcare professionals, along with clear communication about dietary practices is likely to reinforce behaviour change.

“(We are doing) this for our own body; there are no negative aspects in my opinion.”

CoDIRECT develops this into a randomised control trial of the diet intervention as the initial treatment for newly diagnosed patients, conducted at 3 Urban Health Centres (UHCs) of Dhulikhel Municipality due to conclude in early 2028.

Further information can be found at https://www.directclinicaltrial.org.uk/CoDirectNepal.html


A celebration at the Institute of Clinical Trials and Methodology (ICTM) at UCL

The ICTM marked South Asian Heritage Month with a vibrant celebration of culture, community and inspiration at the first event of its kind, bringing colleagues together to recognise and celebrate the rich heritage and contributions of our South Asian staff.

The event was filled with colour, music and conversation as colleagues shared traditional artefacts, henna designs, delicious homemade foods and cultural stories from across South Asia. Many staff embraced the occasion by wearing beautiful traditional clothing, including saris and chunni’s (scarfs), creating a warm and welcoming atmosphere that reflected the diversity of our community.

The event was filled with colour, music and conversation as colleagues shared traditional artefacts, henna designs, delicious homemade foods and cultural stories from across South Asia.

Many staff embraced the occasion by wearing beautiful traditional clothing, including saris and chunnis (scarfs), creating a warm and welcoming atmosphere that reflected the diversity of our community.

A highlight of the event was an inspiring keynote from Rupinder Kaur, award-winning founder of Asian Women Mean Business and a member of the Forbes Coaches Council, where she is the only Sikh woman from the UK.

With a background spanning human resources, psychology, coaching and mentoring, Rupinder has dedicated her career to empowering South Asian women to achieve their personal and professional ambitions.

Rupinder shared her remarkable personal journey, growing up in Wolverhampton during the 1980s as the daughter of migrant manual labourers, through to building a successful business and life in Surrey.

She challenged many of the expectations traditionally placed upon South Asian women and reflected on the courage it took to forge her own path. One particularly memorable story described leaving behind her comfort zone – and her husband and children at home – to climb Mount Kilimanjaro alongside 14 other South Asian women, before documenting the experience for a major streaming platform. Watch Mother Kili here

Perhaps the most powerful message of the afternoon was her reminder that confidence is not the starting point – courage is. By taking courageous first steps, confidence follows, a message that resonated strongly with colleagues across the room.

Delivered by the ICTM EDI Team, the event was created to provide an opportunity for colleagues to learn more about South Asian heritage, celebrate the diversity within our community, strengthen connections across the ICTM and leave feeling inspired.

A huge thank you to everyone who attended, contributed artefacts and food, shared their stories, and helped make this inaugural South Asian Heritage Month celebration such a memorable success. 

We look forward to building on its success in the years to come.


You can learn more about the Network’s commitments in its Strategy for 2025 – 2030 here.

To keep up to date with the work of the Network follow us on LinkedIn or Bluesky.

New QA Specialist sought for Network’s International Registration Review Committee

The UK Registered Clinical Trials Unit (CTU) Network is seeking a highly experienced professional with specialist knowledge in clinical trials to contribute Quality Assurance (QA) expertise to its International Registration Review Committee (IRRC).

The committee is responsible for reviewing all applications for new and ongoing membership and, as such, plays a pivotal role in ensuring that the Network continues to promote excellence and integrity in non-commercial research.

The successful candidate will have a wealth of experience, knowledge, and acumen within the field of non-commercial/academic clinical trials research, demonstrate an excellent understanding of best practice as well as current drivers for change.

A more detailed role description, and information on how to apply, can be found below in the applicant information pack below.

As the collective voice of non-commercial and academic clinical trials units, the Network plays an important role in engaging with Government, funders, regulators, and patients to improve and strengthen clinical research in the UK. The Network is seen internationally as an exemplar for the development of national clinical trials support. It was established in 2007, and its members are committed to setting and sharing good practice and improving standards in clinical trials.

Our Network is funded by its members, and major funders have representation on the Network’s Executive Group, this includes; Cancer Research UK, NIHR, Arthritis UK, as well as devolved nations representation such as Health and Social Care Research Wales.

The deadline for applications is 6pm on 4 September 2026.


Find out more about the work of the Network and Registered CTUs here.

To keep up to date with the work of the Network follow us on LinkedIn or Bluesky.

Network Releases Interim Guidance on Responsible AI Use

The Growing Role of AI in Clinical Trials

The growing availability of advanced artificial intelligence (AI) tools has the potential to reshape how clinical trials are delivered and managed, offering significant potential benefits while also raising complex ethical and governance considerations.

A Collaborative Approach Across the Network

In response, the UK Registered Clinical Trials Units (CTU) Network has established a dedicated group focused on developing and sharing best practice on the use of AI in trial conduct and management. The group draws on individuals with a range of backgrounds from across the Network, bringing a variety of perspectives to this work.

The aim is to ensure that innovation supports high-quality research, enhances impact, and reduces unnecessary waste, whilst ensuring trial integrity

AI Image - Interim Guidance on Responsible AI Use

Interim Guidance on Responsible AI Use

As part of this effort, the Network has issued an interim position statement outlining key principles for the responsible use of AI. This includes a strong emphasis on maintaining ethical standards and regulatory compliance while the field continues to evolve.

“Pending the development of a formal UKCRC CTU Network AI framework and guidance, CTUs using AI technologies should ensure that any use of AI is proportionate, transparent, appropriately governed, and aligned with existing institutional policies, regulatory requirements, and professional standards.

The use of AI must protect the rights, safety, dignity, and confidentiality of research participants and individuals, including compliance with applicable data protection legislation (including UK GDPR), information governance requirements, and ethical obligations.

CTUs should ensure that the use of AI does not compromise scientific integrity, data quality, accountability, or oversight responsibilities. Appropriate consideration should also be given to intellectual property, copyright, confidentiality, contractual obligations, and the ownership and use of data and outputs generated through AI systems.

Any use of AI within trial conduct or CTU operations should be subject to appropriate human oversight, risk assessment, validation, and documentation processes, and should follow local institutional guidance and governance arrangements.
This statement is intended as an interim position while the UKCRC CTU AI Thematic Group develops guidance on the safe and responsible use of AI in clinical trial settings.”

Looking Ahead

The Network’s work reflects a broader recognition across the research community that while AI offers incredible opportunities, its integration must be carefully managed. Balancing innovation with robust governance will be critical to ensuring that AI strengthens, rather than undermines, the integrity and trustworthiness of clinical research.


Find out more about the Network’s Thematic Groups here.

To keep up to date with the work of the Network follow us on LinkedIn or Bluesky.

Marking Red4Research 2026

Red4Research 2026 marks the seventh year of this grassroots campaign to highlight the vital role clinical research plays across all areas of healthcare and celebrate those involved in the trials that improve patient care and outcomes. At its heart, Red4Research is a celebration of the collective effort behind clinical research, from the participants who make studies possible, to the trial teams who design and deliver them.  

Why is research so important?

The importance of clinical research has been repeatedly underscored by the Department of Health and Social Care, who recognise that this is the best way to develop safe and effective new approaches to prevention, diagnosis, and treatment across a wide range of conditions.

Registered Clinical Trials Units (CTUs) specialise in designing and undertaking academic clinical trials that provide the high‑quality evidence needed to inform diagnosis, treatment, and care and improve patient outcomes.

Red4Research 2026

What’s changed this year?

This year’s campaign comes at a pivotal time in the UK research landscape. In April 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA) introduced the most significant package of reforms in more than two decades.

The changes include faster assessment processes for first-in-human trials and the introduction of ‘notifiable trials’, a streamlined route designed to help lower-risk studies begin more quickly and allow modifications to be approved at pace, while maintaining rigorous safety standards.

Behind the scenes, staff working within Registered CTUs have played a crucial role in preparing for and implementing these reforms. Their ongoing collaboration with regulators, sponsors, funders, and participants is helping to ensure that clinical research in the UK remains both safe and impactful.

Across the Network, staff contributions continue to drive world-class, practice-changing research that benefits patients and their families. This year’s campaign offers an opportunity to recognise and celebrate that work more visibly than ever.


Find out more about the work of the Network and Registered CTUs here.

form

Get in touch

If you have any questions about the site, please feel free to contact us. We are always looking for ways to better serve our members - YOU are important to us!

(0113) 3439132

    Sign up to newsletter